Johnson & Johnson’s MedTech and Pharmaceutical Segments to be Placed Under One Brand
Move comes amid company’s shift to focusing on healthcare innovation exclusively.
Johnson & Johnson revealed in a company press release that it will be updating its brand and uniting both its MedTech and pharmaceutical segments under the Johnson & Johnson name. Hoping to concentrate efforts on confronting the toughest health issues and healthcare innovation, the company’s two segments will now be connected to the brand.
According to the organization, Janssen, its pharmaceutical segment, will be renamed Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be named Johnson & Johnson MedTech.
“Our exclusive focus on Innovative Medicine and MedTech solutions enables us to innovate across the full spectrum of healthcare in ways no other company can,” said Joaquin Duato, board chairman, CEO, Johnson & Johnson. “Uniting our diverse businesses under an updated Johnson & Johnson brand reflects our unique ability to reimagine healthcare through transformative innovation, while staying true to our credo values and the level of care that patients and doctors expect of us.”
Reference: Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity. Business Wire. September 14, 2023. Accessed September 15, 2023. https://www.businesswire.com/news/home/20230914626134/en/Johnson-Johnson-Marks-New-Era-as-Global-Healthcare-Company-With-Updated-Visual-Identity/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
